<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 101: Microbiome-Gut-Brain Axis in CBS/PSP</th>
</tr>
<tr>
<td class="label">Microbiome Parameter</td>
<td>CBS/PSP Findings</td>
</tr>
<tr>
<td class="label">Alpha diversity</td>
<td>Reduced in PSP patients</td>
</tr>
<tr>
<td class="label">Firmicutes/Bacteroidetes ratio</td>
<td>Altered in tauopathies</td>
</tr>
<tr>
<td class="label">Prevotella species</td>
<td>May be reduced</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>Variable changes</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>May be decreased</td>
</tr>
<tr>
<td class="label">Enterobacteriaceae</td>
<td>May be increased</td>
</tr>
<tr>
<td class="label">SCFA</td>
<td>Role in Neuroprotection</td>
</tr>
<tr>
<td class="label">Butyrate</td>
<td>Anti-inflammatory, HDAC inhibition</td>
</tr>
<tr>
<td class="label">Propionate</td>
<td>Immune modulation, metabolism</td>
</tr>
<tr>
<td class="label">Acetate</td>
<td>Energy source, epigenetic effects</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Prebiotic fiber</td>
<td>SCFA production enhancement</td>
</tr>
<tr>
<td class="label">Butyrate supplementation</td>
<td>Direct anti-inflammatory</td>
</tr>
<tr>
<td class="label">Butyrate-producing probiotics</td>
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 101: Microbiome-Gut-Brain Axis in CBS/PSP</th>
</tr>
<tr>
<td class="label">Microbiome Parameter</td>
<td>CBS/PSP Findings</td>
</tr>
<tr>
<td class="label">Alpha diversity</td>
<td>Reduced in PSP patients</td>
</tr>
<tr>
<td class="label">Firmicutes/Bacteroidetes ratio</td>
<td>Altered in tauopathies</td>
</tr>
<tr>
<td class="label">Prevotella species</td>
<td>May be reduced</td>
</tr>
<tr>
<td class="label">Lactobacillus</td>
<td>Variable changes</td>
</tr>
<tr>
<td class="label">Bifidobacterium</td>
<td>May be decreased</td>
</tr>
<tr>
<td class="label">Enterobacteriaceae</td>
<td>May be increased</td>
</tr>
<tr>
<td class="label">SCFA</td>
<td>Role in Neuroprotection</td>
</tr>
<tr>
<td class="label">Butyrate</td>
<td>Anti-inflammatory, HDAC inhibition</td>
</tr>
<tr>
<td class="label">Propionate</td>
<td>Immune modulation, metabolism</td>
</tr>
<tr>
<td class="label">Acetate</td>
<td>Energy source, epigenetic effects</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Prebiotic fiber</td>
<td>SCFA production enhancement</td>
</tr>
<tr>
<td class="label">Butyrate supplementation</td>
<td>Direct anti-inflammatory</td>
</tr>
<tr>
<td class="label">Butyrate-producing probiotics</td>
<td>Targeted SCFA enhancement</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Assessment Method</td>
</tr>
<tr>
<td class="label">Zonulin</td>
<td>Serum ELISA</td>
</tr>
<tr>
<td class="label">LPS</td>
<td>Serum measurement</td>
</tr>
<tr>
<td class="label">FABP2</td>
<td>Intestinal fatty acid binding</td>
</tr>
<tr>
<td class="label">Claudin-3</td>
<td>Tissue biopsy</td>
</tr>
<tr>
<td class="label">Therapeutic Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Glutamine</td>
<td>Intestinal repair</td>
</tr>
<tr>
<td class="label">Zinc carnosine</td>
<td>Barrier protection</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Polyphenols</td>
<td>Antioxidant, barrier</td>
</tr>
<tr>
<td class="label">TMAO Level</td>
<td>CBS/PSP Relevance</td>
</tr>
<tr>
<td class="label">Elevated in some patients</td>
<td>Associated with vascular pathology</td>
</tr>
<tr>
<td class="label">Correlates with inflammation</td>
<td>May worsen neurodegeneration</td>
</tr>
<tr>
<td class="label">Modifiable through diet</td>
<td>Actionable biomarker</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Prion-like spreading</td>
<td>Strong in alpha-synuclein</td>
</tr>
<tr>
<td class="label">Inflammation-enhanced aggregation</td>
<td>Moderate evidence</td>
</tr>
<tr>
<td class="label">Microbial proteins as seeds</td>
<td>Emerging research</td>
</tr>
<tr>
<td class="label">Probiotic Strain</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Bifidobacterium breve</td>
<td>Anti-inflammatory, SCFA</td>
</tr>
<tr>
<td class="label">Lactobacillus plantarum</td>
<td>Barrier enhancement</td>
</tr>
<tr>
<td class="label">Lactobacillus rhamnosus</td>
<td>GABA modulation</td>
</tr>
<tr>
<td class="label">Multi-strain formulations</td>
<td>Synergistic effects</td>
</tr>
<tr>
<td class="label">Probiotic Type</td>
<td>Potential Benefit</td>
</tr>
<tr>
<td class="label">Single strains</td>
<td>Targeted effects</td>
</tr>
<tr>
<td class="label">Multi-strain</td>
<td>Broader modulation</td>
</tr>
<tr>
<td class="label">Spore-based</td>
<td>Stability</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">GUT-PARFECT trial</td>
<td>Single FMT</td>
</tr>
<tr>
<td class="label">Finnish trial</td>
<td>FMT</td>
</tr>
<tr>
<td class="label">Meta-analysis</td>
<td>FMT</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Evidence</td>
<td>No CBS/PSP-specific data</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>Procedure-related risks</td>
</tr>
<tr>
<td class="label">Availability</td>
<td>Limited to clinical trials</td>
</tr>
<tr>
<td class="label">Recommendation</td>
<td>Not standard of care</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">High fiber</td>
<td>SCFA production</td>
</tr>
<tr>
<td class="label">Olive oil polyphenols</td>
<td>Antioxidant</td>
</tr>
<tr>
<td class="label">Omega-3 fatty acids</td>
<td>Membrane fluidity</td>
</tr>
<tr>
<td class="label">Reduced red meat</td>
<td>Lower TMAO</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Implementation</td>
</tr>
<tr>
<td class="label">Soluble fiber</td>
<td>Oats, legumes, fruits</td>
</tr>
<tr>
<td class="label">Insoluble fiber</td>
<td>Whole grains, vegetables</td>
</tr>
<tr>
<td class="label">Prebiotic fiber</td>
<td>Inulin, FOS</td>
</tr>
<tr>
<td class="label">Resistant starch</td>
<td>Cool potatoes, legumes</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Score</td>
</tr>
<tr>
<td class="label">Mediterranean diet</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Fiber optimization</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Probiotic supplementation</td>
<td>Modest</td>
</tr>
<tr>
<td class="label">Prebiotic fiber</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">TMAO reduction</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">FMT</td>
<td>No evidence in CBS/PSP</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">MAPT</td>
<td>Tau protein</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>Progranulin</td>
</tr>
<tr>
<td class="label">VCP</td>
<td>Protein quality control</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Microglial activation</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Probiotics</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Prebiotics</td>
</tr>
<tr>
<td class="label">Various</td>
<td>Dietary interventions</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Zonulin</td>
<td>Serum ELISA</td>
</tr>
<tr>
<td class="label">LPS</td>
<td>Serum ELISA</td>
</tr>
<tr>
<td class="label">TMAO</td>
<td>Mass spectrometry</td>
</tr>
<tr>
<td class="label">SCFAs</td>
<td>Gas chromatography</td>
</tr>
<tr>
<td class="label">Fecal calprotectin</td>
<td>Stool</td>
</tr>
</table>
The gut-brain axis represents a bidirectional communication network linking the gastrointestinal tract and its resident microbiome with the central nervous system[@cryan2019]. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4R-tauopathies, emerging evidence suggests that gut microbiome dysbiosis may contribute to disease pathogenesis through multiple mechanisms including neuroinflammation, protein aggregation propagation, and metabolic dysfunction[@vogt2017]. This section provides comprehensive coverage of gut microbiome alterations, bacterial metabolite effects, leaky gut syndrome, alpha-synuclein spreading hypotheses, and therapeutic interventions targeting the microbiome-gut-brain axis in CBS/PSP.
The communication between the gut and brain occurs through neural (vagus nerve, enteric nervous system), endocrine (HPA axis, gut hormones), immune (cytokines, LPS), and metabolic (SCFAs, bile acids) pathways[@parker2018]. Understanding these pathways provides insight into how gut dysbiosis may influence tau pathology propagation and neuroinflammatory processes in CBS/PSP.
While direct studies of gut microbiome in CBS and PSP remain limited compared to Parkinson's disease, emerging evidence suggests characteristic dysbiosis patterns that may contribute to disease pathogenesis:
The gut microbiome may influence CBS/PSP pathogenesis through several mechanisms:
Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are produced by bacterial fermentation of dietary fiber in the colon[@silva2020]:
SCFA-enhancing strategies for CBS/PSP:
Leaky gut syndrome refers to increased intestinal permeability, allowing bacterial components and toxins to translocate into systemic circulation[@camilleri2019]:
Gut barrier assessment in CBS/PSP:
LPS, a component of gram-negative bacterial cell walls, triggers powerful inflammatory responses through TLR4 activation[@lukiw2020]:
LPS and tauopathies:
TMAO is produced by gut bacteria from dietary choline and carnitine[@jov2020]:
These protein-bound uremic toxins from gut bacterial metabolism accumulate in renal insufficiency and may have neurotoxic effects:
The Braak hypothesis proposes that alpha-synuclein pathology may originate in the peripheral nervous system and propagate to the brain via prion-like spreading[@braak2003]:
Relevance to CBS/PSP:
Evidence summary:
FMT has been investigated primarily in Parkinson's disease with mixed results[@tune2024]:
Current status:
The Mediterranean diet demonstrates consistent benefits for neurodegenerative diseases through microbiome modulation[@tsai2022]:
The ketogenic diet may influence the gut-brain axis through:
The MIND diet combines Mediterranean and DASH diets with specific neuroprotective components:
Target: 25-35g dietary fiber daily
This section integrates with previously covered topics:
Based on current evidence for microbiome-targeted interventions:
The gut-brain axis represents an emerging therapeutic target in CBS/PSP. While direct evidence for microbiome interventions in CBS/PSP remains limited, the strong mechanistic rationale and supportive data from related tauopathies and Parkinson's disease support a hierarchical approach:
The bidirectional communication between gut and brain provides multiple intervention points. Patients should be counseled that microbiome-targeted approaches are supportive rather than disease-modifying, though they may enhance overall therapeutic efficacy when combined with other interventions.
Future directions include identifying biomarkers for patient selection, developing personalized microbiome interventions, and conducting CBS/PSP-specific clinical trials.